Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
Anna L. Peljto(University of Colorado Anschutz Medical Campus), David A. Schwartz(University of Colorado Anschutz Medical Campus), Imre Noth(University of Chicago), Tasha E. Fingerlin(University of Colorado Denver), Elissa Murphy(University of Colorado Denver), Lori Silveira(University of Colorado Denver), Cheryl Markin(Vanderbilt University), Kathleen O. Lindell(University of Pittsburgh), Scott D. Seiwert, Kevin K. Brown(Boston Children's Hospital), Karl Kossen, Joe G. N. Garcia(Johns Hopkins University), Kevin F. Gibson(University of Pittsburgh), Marvin I. Schwarz(San Francisco General Hospital), James E. Loyd, Shwu‐Fan Ma(University of Chicago), Thomas J. Richards(University of Pittsburgh), Naftali Kaminski(Yale University), Yingze Zhang(University of Pittsburgh), Janet Talbert(University of Colorado Denver), Mark P. Steele(Vanderbilt University), Max A. Seibold(National Jewish Health)
Cited by 456
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
|New England Journal of Medicine|2007|1.4k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Toll-like Receptor 4 Polymorphisms and Atherogenesis
|New England Journal of Medicine|2002|1k